The impact of micronized progesterone on breast cancer risk: a systematic review

@article{Stute2018TheIO,
  title={The impact of micronized progesterone on breast cancer risk: a systematic review},
  author={Petra Stute and Ludwig Wildt and Joseph Neulen},
  journal={Climacteric},
  year={2018},
  volume={21},
  pages={111 - 122}
}
Abstract Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. The debate on bioidentical hormones including micronized progesterone has increased in recent years. Based on a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronized progesterone on the mammary gland, an international expert panel’s recommendations are as follows: (1) estrogens combined with oral (approved) or vaginal… 
31 Citations
The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue
  • X. Ruan, A. Mueck
  • Medicine
    Hormone molecular biology and clinical investigation
  • 2018
TLDR
Experimental research has demonstrated that certain synthetic progestogens, but not progesterone and to some extent also not dydrogesterone, can accelerate the proliferation of breast cancer cells in vitro and in animal studies via special cell membrane components which recently also detected in patients with BC.
Progestins in menopausal hormone therapy and breast cancer risk: The debate continues
TLDR
Debunking the idea that all progestins will increase breast cancer risk is vital to the insight into progestin-specific effects in breast cancer, which is complex and can involve multiple steroid receptors and non-classical mechanisms.
Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference
TLDR
Micronized progesterone and dydrogesterone appear to be the safest options, with lower associated cardiovascular, thromboembolic, and breast cancer risks compared with other progestogens, and are the first-choice options for use in ‘special situations,’ such as in women with high-density breast tissue, diabetes, obesity, smoking, and risk factors for venous throm boembolism.
Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial
TLDR
Results of secondary outcomes suggest that E2/P4 may not be associated with increased risk of abnormal mammograms versus placebo, and the incidence of breast tenderness was low relative to most of the rates reported in other studies using hormone therapy.
Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review
TLDR
A systematic literature review on the impact of MHT containing MP on body weight, body mass index (BMI), and glucose metabolism, the following conclusions can be drawn: estrogens combined with MP either do not change or reduce body weight in normal weight postmenopausal women.
Changes in breast density during hormone treatment with transdermal estrogens alone or in combination with progesterone
TLDR
No increased breast density was observed in women on HT treatment, nor did the authors observe an increase according to HT type, but the difference in breast density loss was smaller in the HT group versus the control group.
Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.
TLDR
The role of hormone therapy in menopausal patients with breast cancer and gynecologic malignancies is reviewed to determine whether it is considered safe in low-risk cancers but should be avoided in high-risk subtypes.
TRANSDERMAL ESTRADIOL’S USE IN MENOPAUSE: An Evidence-Based Affirmation
A thorough literature review affirms that in peri-and postmenopausal (PMP) women, estradiol (E2) effectively relieves vasomotor (VMS) and vulvovaginal atrophy (VVA) symptoms, while increasing bone
Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms.
  • L. Newson, A. Lass
  • Medicine
    The British journal of general practice : the journal of the Royal College of General Practitioners
  • 2018
TLDR
The role of hormone replacement therapy (HRT) in the management of menopausal symptoms is discussed, and the advantages of different types and preparations of HRT are considered, based on the current medical evidence.
The dangers of compounded bioidentical hormone replacement therapy.
  • L. Newson, J. Rymer
  • Medicine
    The British journal of general practice : the journal of the Royal College of General Practitioners
  • 2019
TLDR
The subsequent sub-analysis of this study revealed reassuring and positive results to support the use of HRT, especially in younger women.
...
1
2
3
4
...

References

SHOWING 1-10 OF 54 REFERENCES
The impact of micronized progesterone on the endometrium: a systematic review
TLDR
Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection, according to an international expert panel’s recommendations on MHT containing micronized progesterone.
Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
TLDR
Observational studies suggest that in menopausal women, estrogen and progesterone use may be associated with lower breast cancer risk compared to synthetic progestin.
Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women
TLDR
The largest-to-date randomized trial comparing the effects of hormone replacement therapy (HRT) and a placebo concluded that the continuous use of an oral combination of conjugated equine estrogens (CEE) and medroxy-progesterone acetate (MPA) increases the risk of breast cancer.
Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys
TLDR
Oral micronized progesterone has a more favorable effect on risk biomarkers for postmenopausal breast cancer than medroxyprogesterone acetate, and both progestogens significantly attenuated E2 effects on body weight, endometrium, and the TFF1 marker of estrogen receptor activity in the breast.
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study
TLDR
The findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
TLDR
It is suggested that, for some EP-MHT, the timing of treatment initiation transiently modulates the risk of breast cancer and that, when initiated close to menopause, even short durations of use are associated with an increased breast cancer risk.
Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
TLDR
The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progester one and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+/PR-, and to affect both ductal and lobular carcinomas.
Transcriptional profiles of progestogen effects in the postmenopausal breast
TLDR
It is suggested that a standard dose of oral E2-+ MPA has a more pronounced effect on gene expression in the breast compared to E2 alone or E2 + P4 and that promotional effects of E2+MPA may be mediated in part by increased EGFR activity.
Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort
TLDR
The results suggest residual increases in breast cancer risk several years after MHT cessation, which are restricted to long-term treatments, and whether increases persist more than 10 years after cessation deserves continuing investigation.
Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis
TLDR
Estradiol-only therapy carries no risk for breast cancer, while the breast cancer risk varies according to the type of progestogen, in the analysis of estradiol-progestogen therapy.
...
1
2
3
4
5
...